Status:
COMPLETED
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The study aims to assess the effects of single dose and repeated weekly dosing of 50mg d-cycloserine versus placebo on cognitive and memory functioning in schizophrenia patients. The study will also e...
Detailed Description
This is a ten-week, parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 2, 3. 4, 5, 6, 7, 8 \& 10 of once-weekly oral D-cycloserine 50 mg added to a stable dose of ant...
Eligibility Criteria
Inclusion
- Male or female
- Age 18-65 years
- Diagnosis of schizophrenia or schizoaffective disorder, depressed type
- Stable dose of antipsychotic for at least 4 weeks.
- Able to provide informed consent
- Able to complete a cognitive battery
Exclusion
- Current treatment with clozapine
- Dementia
- Seizure disorder
- Unstable medical illness
- Active substance abuse
- Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00455702
Start Date
July 1 2004
End Date
April 1 2007
Last Update
August 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114